Trial Profile
An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs PSI 697 (Primary)
- Indications Scleritis
- Focus Adverse reactions
- Sponsors Wyeth
- 25 Jun 2014 New trial record